Cui Yong, Dong Chang, Wu Bing-Qun, Duan Xin-Chun, Shi Guan, Gong Min, Wang Tian-You
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C44-8. doi: 10.4103/0973-1482.163838.
Esophageal squamous cell carcinoma (ESCC) is a frequently occurring cancer with poor prognosis despite combined therapeutic strategies. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) in Chinese patients with ESCC.
Formalin-fixed paraffin-embedded surgically resected tumor samples were obtained from 140 randomly selected Chinese patients with ESCC. Sections were immunohistochemically stained for COX-2, VEGF, and EGFR. The correlations between clinicopathological features and the high expression of COX-2, VEGF, and EGFR were analyzed using the Statistical Package for the Social Sciences 19.0 software (IBM Inc., Chicago, IL, USA).
In the present study, high expression of COX-2, EGFR, and VEGF was found in 64.3%, 62.1%, and 65.0%, respectively. Results showed that COX-2 overexpression was significantly correlated with degree of differentiation (P = 0.000), and lymph node metastasis (negative/positive, P = 0.002). EGFR and VEGF overexpression was significantly correlated with a differentiated degree, T stage, N stage, and tumor, node, metastases stage.
High expression of COX-2, EGFR, and VEGF is an unfavorable prognostic factor in ESCC, and could be used as a poor prognosis indicator for the ESCC patients. Targeting therapy to these three targets should be considered to the combined treatment in ESCC.
食管鳞状细胞癌(ESCC)是一种常见癌症,尽管采用了联合治疗策略,但其预后较差。本研究的目的是进一步阐明环氧合酶-2(COX-2)、血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)免疫组化表达在中国ESCC患者中的临床病理意义。
从140例随机选择的中国ESCC患者中获取手术切除的肿瘤样本,用福尔马林固定、石蜡包埋。对切片进行COX-2、VEGF和EGFR的免疫组化染色。使用社会科学统计软件包19.0(美国伊利诺伊州芝加哥市IBM公司)分析临床病理特征与COX-2、VEGF和EGFR高表达之间的相关性。
在本研究中,COX-2、EGFR和VEGF的高表达分别为64.3%、62.1%和65.0%。结果显示,COX-2过表达与分化程度(P = 0.000)和淋巴结转移(阴性/阳性,P = 0.002)显著相关。EGFR和VEGF过表达与分化程度、T分期、N分期及肿瘤-淋巴结-转移分期显著相关。
COX-2、EGFR和VEGF的高表达是ESCC的不良预后因素,可作为ESCC患者预后不良的指标。在ESCC的联合治疗中应考虑针对这三个靶点的靶向治疗。